Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Robert McWhirter commented about whether HRX-T, TCS-T, TNC-X, YRI-T, AGU-T, IMP-T, PHO-T, CSW.A-T, PHM-X, AXY-T, SJ-T, DHX.B-T, OEE-X, NGC-X, GPH-X, TOS-T, PLI-T, ENGH-T, HBM-T, RSI-T, HLTH-A, JKPTF-5, CAE-T, VRX-T, CZO-X, FLY-X, RNW-T, LB-T, CBX-X, ROI-X are stocks to buy or sell.
- Page 2/5
- Next Page
If you are a hospital and need to sterilize some exotic equipment, the advantage of this company’s product is that it will do it very quickly and very economically. The equipment uses a combination of hydrogen peroxide in a cabinet, where you can put in unusual shaped objects. Recently got FDA approval. Also, they are using their old methodology for another kind of application. There is a definite need for their product. Forecasted earnings for 2017 is only $.02, so a lot of the good news has already been discounted. Not cheap.
He doesn’t follow this company, but generic comments on graphite is that if you are keen on Elon Musk and Tesla, you should be keen on graphite. There is literally more graphite in lithium ion batteries than there is lithium. However, graphite is not all the same. You want really, really course graphite for batteries. You can use really, really fine graphite, to make pencils. Thinks this is a great opportunity, and hopefully the market will end up coming to the realization that you need graphite.
He doesn’t follow this company, but generic comments on graphite is that if you are keen on Elon Musk and Tesla, you should be keen on graphite. There is literally more graphite in lithium ion batteries than there is lithium. However, graphite is not all the same. You want really, really course graphite for batteries. You can use really, really fine graphite, to make pencils. Thinks this is a great opportunity, and hopefully the market will end up coming to the realization that you need graphite.
This has a partnership with Cisco (CSCO-Q) as well as Mazak, a large Japanese based robot making company. Their software connects machines on the factory floor to the top floor. Because of concerns of viruses between the factory floor and the top floor, Cisco basically provided a buffer between the 2. Cisco gave this company a huge endorsement. Thinks the company will do well. In the near term, they are ramping up expenses and hiring sales and support staff. On a 2-3 year basis, the stock will do well because of what they offer. In the near term you are not going to see a huge improvement in earnings, until those new sales hires start to pan out.
Expected to earn $.35 in June/2016, growing to $.40 in 2017, about a 15% lift. Dividend is probably as big as you are going to see in the near term. They grow by acquisition, and it should continue to do well. Has a library of children’s videos, which they can continue to build out at almost no cost. They hope to get big enough that someone like Disney (DIS-N) will buy out their videos. There is also the potential of someone like Netflix (NFLX-Q) taking a run at them. Stock seems to be relatively expensive.
(Market Call Minute.) This continues to have specialized measurement. A huge free cash flow generator. There has been a change in management. The underlying business continues to do well. They have the cash, and there is a question as to whether they will be acquiring something that is profitable.
(Market Call Minute.) It looks like corn and other commodities are turning down. There is a need for increased food production globally on a longer-term basis, but if it turns out that the farmers don’t have the cash in their jeans to be able to afford it, he would be cautious in the near term on all fertilizer stocks.
Roughly a $200 million market cap company. They process about $80 million bill payments per year with a value of about $9 billion. Have significant business leverage. They’ve grown by acquisition. A recent 18% increase in sales, led to an increase of over 100% in free cash flow, earnings and EBITDA. They have an attractive 4.2% cash flow yield. Earnings estimates have increased 18% in the last 90 days.
He has a very tiny position. There are 2 parts to their business. 1.) Taking a bag of blood plasma, and using their proprietary extraction method, extracting some high-value protein. They’ve identified 5 orphan drugs, and 2017-2018 is when they should start extracting those drugs and making significant cash flow. 2.) Also, has a PBI4050 drug, which basically targets fibrosis of many organs, as well as potential applications in diabetes. If successful, it has the ability to end up being an absolute kind of company maker with a vengeance. A speculative company. If you are willing to take a flyer, you will know in about 2 years.